IMR Press / RCM / Volume 11 / Issue 4 / DOI: 10.3909/ricm0557
Open Access Review
Progesterone, Progestins, and the Heart
Show Less
12 University of Southern California, Los Angeles, CA
Rev. Cardiovasc. Med. 2010 , 11(4), 228–236; https://doi.org/10.3909/ricm0557
Published: 30 December 2010
Abstract
All combination hormone replacement regimens contain estrogen and a progestational agent. The Women’s Health Initiative trial demonstrated that taking the combination of conjugated estrogen and medroxyprogesterone resulted in a higher risk of myocardial infarction and stroke in the study population. However, not all progestational agents are alike in their cardiovascular properties. This article reviews what is known about the most commonly prescribed agents: progesterone, medroxyprogesterone, norethindrone,and norethindrone acetate. We compare data on markers of lipid metabolism, inflammation, and clotting function, and review studies that measure their direct effects on cardiac vessels.
Keywords
Progesterone
Progestin
Coronary heart disease
Myocardial infarction
Biomarkers
Share
Back to top